Valerio Therapeutics Société anonyme (EPA:ALVIO)
France · Delayed Price · Currency is EUR 0.1930
+0.0050 (2.66%)
Jun 3, 2026, 5:35 PM CET
Valerio Therapeutics Société anonyme Company Description
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies.
The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody– drug conjugates, and chimeric antigen receptors.
The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023.
Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Valerio Therapeutics Société anonyme
| Country | France |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Julien Miara |
Contact Details
Address: 49, boulevard du GEnEral Martial Valin Paris, 75015 France | |
| Phone | 33 1 45 58 76 00 |
| Website | valeriotx.com |
Stock Details
| Ticker Symbol | ALVIO |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0010095596 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Antoine Barouky | Deputy Chief Executive Officer and Director |
| Julien Miara | Chief Executive Officer and Director |
| Wael Jdey Ph.D. | Chief Technology Officer |
| Olivier Demaria Ph.D. | Chief Scientific Officer |
| Lucile Dez | Director of Human Resources and Administration |